Drug Profile
Research programme: CCR5 antagonists - Boehringer Ingelheim
Latest Information Update: 18 May 2017
Price :
$50
*
At a glance
- Originator Boehringer Ingelheim
- Class
- Mechanism of Action CCR5 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported HIV infections
Most Recent Events
- 16 May 2017 Ogeda has been acquired by and became a wholly-owned subsidiary of Astellas Pharma
- 19 Oct 2016 Euroscreen is now called Ogeda